ArticleBJS open2026
The fate of the contralateral limb after major lower limb amputation for peripheral arterial disease or diabetes mellitus.
Article in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe contralateral limb is at risk after major lower limb amputation (MLLA) for peripheral arterial disease or diabetes mellitus due to the systemic nature of these diseases, with a subsequent bilateral MLLA required in over 10% of patients. The present study aims to determine the natural history of the contralateral limb after MLLA for peripheral arterial disease or diabetes.
methodsA single-centre retrospective cohort study of patients undergoing MLLA for peripheral arterial disease or diabetes between January 2013 and July 2023 was performed. The primary outcome was clinically relevant contralateral limb disease (CR-CLD), defined as symptomatic disease of the contralateral limb or asymptomatic disease requiring prophylactic intervention. Statistical analysis used both survival analysis and competing risk modelling techniques.
resultsA total of 531 patients were included, with 175 (33%) going on to develop CR-CLD. The leading aetiology was chronic limb-threatening ischaemia, with 79.7% of these patients presenting with tissue loss. A total of 67% of CR-CLD presented by 1 year and 81% by 2 years after index MLLA. A diagnosis of diabetes, chronic peripheral arterial disease, ischaemic heart disease, and previous contralateral vascular intervention were identified as independent risk factors for the development of CR-CLD on multivariable analysis. A total of 72.6% of patients with CR-CLD underwent intervention, 28.6% of these requiring contralateral MLLA. For those not undergoing intervention, 56.3% were turned down due to co-morbidity or frailty.
conclusionCR-CLD after MLLA is common, and presents early after index MLLA but with late-stage clinical disease. High-risk groups are identifiable. Outcomes are poor, with many patients undergoing a contralateral MLLA or being palliated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.